Shire CEO thinks he can beat $500M in postmerger cost savings

Emily Wasserman

may have clinched its $ 32 billion deal to buy Baxalta, but not everyone is breaking out the confetti. Some analysts aren't sold on the tie-up, saying they expected more in the way of and still are perplexed by what Baxalta brings to the table.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS